Literature DB >> 18246329

Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum.

Brenda J Gehrke1, Vladimir I Chefer, Toni S Shippenberg.   

Abstract

RATIONALE: Acute systemic administration of salvinorin A, a naturally occurring kappa-opioid receptor (KOPr) agonist, decreases locomotion and striatal dopamine (DA) overflow.
OBJECTIVES: Conventional and quantitative microdialysis techniques were used to determine whether salvinorin A infusion into the dorsal striatum (DSTR) decreases DA overflow by altering DA uptake or release. The influence of repeated salvinorin A administration on basal DA dynamics and cocaine-evoked alterations in DA overflow and locomotion was also assessed.
MATERIALS AND METHODS: Salvinorin A was administered via the dialysis probe (0; 20-200 nM) or via intraperitoneal (i.p.) injection (1.0 or 3.2 mg/kg per day x 5 days). The effects of a challenge dose of cocaine were examined 48 h after repeated salvinorin treatment.
RESULTS: Retrodialysis of salvinorin A produced a dose-related, KOPr antagonist reversible, decrease in DA levels. Extracellular DA levels were decreased whereas DA extraction fraction, which provides an estimate of DA uptake, was unaltered. In contrast to its acute administration, repeated salvinorin A administration did not modify dialysate DA levels. Similarly, neither basal extracellular DA levels nor DA uptake was altered. Unlike synthetic KOPr agonists, prior repeated administration of salvinorin A did not attenuate the locomotor activating effects of an acute cocaine (20 mg/kg, i.p.) challenge. However, cocaine-evoked DA overflow was enhanced.
CONCLUSIONS: These data demonstrate that acute, but not repeated, salvinorin A administration decreases mesostriatal neurotransmission and that activation of DSTR KOPr is sufficient for this effect. Differences in the interaction of salvinorin and synthetic KOPr agonists with cocaine suggest that the pharmacology of these agents may differ.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18246329      PMCID: PMC3700373          DOI: 10.1007/s00213-007-1067-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Kappa agonist-induced reduction in dopamine release: site of action and tolerance.

Authors:  B A Donzanti; J S Althaus; M M Payson; P F Von Voigtlander
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1992-11

2.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors:  R Spanagel; A Herz; T S Shippenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Psychotomimesis mediated by kappa opiate receptors.

Authors:  A Pfeiffer; V Brantl; A Herz; H M Emrich
Journal:  Science       Date:  1986-08-15       Impact factor: 47.728

4.  Enhanced responsiveness to novelty and cocaine is associated with decreased basal dopamine uptake and release in the nucleus accumbens: quantitative microdialysis in rats under transient conditions.

Authors:  Vladimir I Chefer; Irina Zakharova; Toni S Shippenberg
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

5.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

6.  Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists.

Authors:  T S Shippenberg; A Herz
Journal:  Brain Res       Date:  1987-12-08       Impact factor: 3.252

7.  Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine.

Authors:  L H Parsons; A D Smith; J B Justice
Journal:  Synapse       Date:  1991-09       Impact factor: 2.562

8.  Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo.

Authors:  T Endoh; H Matsuura; C Tanaka; H Nagase
Journal:  Arch Int Pharmacodyn Ther       Date:  1992 Mar-Apr

9.  Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors.

Authors:  T S Shippenberg; R Bals-Kubik; A Herz
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

10.  Substance use and related problems: a study on the abuse of recreational and not recreational drugs in Northern Italy.

Authors:  Raimondo Maria Pavarin
Journal:  Ann Ist Super Sanita       Date:  2006       Impact factor: 1.663

View more
  31 in total

Review 1.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

2.  Voluntary ethanol intake predicts κ-opioid receptor supersensitivity and regionally distinct dopaminergic adaptations in macaques.

Authors:  Cody A Siciliano; Erin S Calipari; Verginia C Cuzon Carlson; Christa M Helms; David M Lovinger; Kathleen A Grant; Sara R Jones
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 3.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

4.  Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.

Authors:  Jacob M Hooker; Thomas A Munro; Cécile Béguin; David Alexoff; Colleen Shea; Youwen Xu; Bruce M Cohen
Journal:  Neuropharmacology       Date:  2009-07-08       Impact factor: 5.250

Review 5.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

6.  Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat.

Authors:  Veronica Serra; Liana Fattore; Maria Scherma; Roberto Collu; Maria Sabrina Spano; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

Review 7.  Dynorphin, stress, and depression.

Authors:  Allison T Knoll; William A Carlezon
Journal:  Brain Res       Date:  2009-09-24       Impact factor: 3.252

8.  Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Authors:  Denise S Simpson; Kimberly M Lovell; Anthony Lozama; Nina Han; Victor W Day; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Journal:  Org Biomol Chem       Date:  2009-07-14       Impact factor: 3.876

Review 9.  Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse.

Authors:  Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

10.  Opposing actions of chronic stress and chronic nicotine on striatal function in mice.

Authors:  Ramiro Salas; Mariella De Biasi
Journal:  Neurosci Lett       Date:  2008-05-16       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.